Grant ID RP210092
Awarded On August 18, 2021
Title Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Kendra Carmon
Cancer Sites Colorectal
Contracted Amount $250,000*

*Pending contract negotiation

Lay Summary

Drug resistance, metastasis, and tumor relapse continue to be leading causes of colorectal cancer (CRC)-related deaths. Current therapies only provide a limited increase in survival to the subset of advanced CRC patients that respond, demonstrating the need for innovative therapeutic strategies to improve outcome. Cancer stem cells (CSCs) are a subpopulation of tumor cells shown to be major drivers of tumor growth, metastasis, and relapse. Therefore, an effective cancer treatment could be one that destroys CSCs. LGR5 is a protein highly upregulated in CRC with low expression in normal healthy tissues and is found on the surface of CSCs. We generated anti-LGR5 antibody-drug conjugates (ADCs) ...

Read More